![[Bio USA] GI Innovation unveils next-gen immunotherapy pipeline](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F06%2F18%2Fnews-p.v1.20250618.d08a9f94aea74f3da95329681a945806_T1.jpg&w=3840&q=100)
[Bio USA] GI Innovation unveils next-gen immunotherapy pipeline
Leading the presentation was Yun Nari, head of GI Innovation's clinical strategy, who introduced the company's new drug development pipeline and global business roadmap. A licensed pharmacist, Yun joined the company's board of directors in March and is expected to play a pivotal role in accelerating clinical decision-making, an essential function in GI Innovation's core business of clinical-stage drug development.
A key highlight was the unveiling of GI-128, a novel immuno-oncology candidate that leverages macrophage engagement, an emerging target in next-generation cancer therapies. The company also spotlighted its trispecific antibody pipeline, designed to surpass the current generation of aPD-(L)1/VEGF bispecific antibodies, which are gaining significant traction in the global oncology space.
'This year's Bio USA is a premier platform that brings together leading global investors and pharmaceutical companies,' said Jang Myoung-ho, CEO and founder of GI Innovation. 'It presented the perfect opportunity to demonstrate the competitiveness of our pipeline and global expansion strategy. We plan to actively explore a variety of partnership opportunities, including technology licensing, co-development deals and strategic investments.'
Meanwhile, the growing interest in aPD-(L)1/VEGF bispecific antibodies in the immuno-oncology sector has led to a surge in high-value deals. Bristol Myers Squibb recently entered into a licensing agreement with German biotech firm BioNTech, paying an upfront sum of approximately $1.5 billion, with the total deal valued at around $11.1 billion. Likewise, Merck & Co. signed a deal last year with China-based LaNova Medicines, worth $588 million upfront and up to $2.7 billion in milestone payments.
Building on this trend, GI Innovation's trispecific antibody platform integrates the company's proprietary aPD-L1 antibody, a VEGF antibody and a macrophage engager into a single molecule. The design aims to overcome the therapeutic limitations of bispecific antibodies by stimulating a more robust immune response within the tumor microenvironment, the company explained.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
7 hours ago
- Korea Herald
Lee to dispatch special envoys to Poland, Vietnam, Australia, Germany
President Lee Jae Myung will dispatch special envoys to Poland, Vietnam, Australia and Germany to deliver personal letters and discuss ways to expand bilateral cooperation, the presidential office said Friday. The envoys will depart consecutively starting Sunday and will meet with key officials in each country to convey Lee's message and explore opportunities to enhance friendly and cooperative ties, according to presidential spokesperson Kang Yu-jung. The delegation to Poland, comprised of Reps. Park Jie-won, Eeo Ki-kyu and Jin Sun-mee of the ruling Democratic Party, will leave on Sunday for a five-day visit. During their stay, they plan to meet with government and parliamentary officials to review the growing defense industry cooperation between the two nations and discuss ways to further develop their strategic partnership, Kang said. The Vietnam delegation will be led by former lawmaker Lee In-ki and include two additional DP lawmakers and will depart on Monday. The group will deliver Seoul's commitment to strengthening the comprehensive strategic partnership between the countries and will hold wide-ranging discussions on expanding practical cooperation particularly in infrastructure and energy. Former National Assembly Speaker Kim Jin-pyo will lead the Australian delegation, which is scheduled to leave on Monday for a four-day trip. The delegation will engage with Australian officials to discuss defense and defense industry ties, trade and supply chains and energy cooperation. The delegation to Germany will be headed by Lee Seog-yeon, a former minister of government legislation, and will depart on Wednesday. They plan to meet with German government officials to explore deeper cooperation in key sectors, such as manufacturing, digital transformation and artificial intelligence, as well as to exchange views on regional and global affairs. (Yonhap)
Korea Herald
11 hours ago
- Korea Herald
Seoul shares up for 3rd day amid US tariff uncertainties; won sharply down
Seoul shares closed slightly higher Friday, extending their winning streak to a third day, as investors kept a close eye on the ongoing tariff negotiations between South Korea and the United States, which is expected to have a huge impact on the economy. The Korean won lost ground against the US dollar. The benchmark Korea Composite Stock Price Index added 5.6 points, or 0.18 percent, to close at 3,196.05. Trade volume was moderate at 385.7 million shares worth 9.8 trillion won ($7.1 billion), with losers outnumbering winners 504 to 370. Foreigners and institutions bought shares worth 268.9 billion won and 110.4 billion won, respectively, while retail investors unloaded 461.3 billion won. Overnight, Wall Street closed mixed, with the tech-heavy Nasdaq composite and the S&P 500 up 0.18 percent and 0.07 percent, respectively, while the Dow Jones Industrial Average shed 0.7 percent. Investors were paying close attention to whether Seoul will also strike a trade deal with Washington following Japan as Korea's top trade officials met with US Commerce Secretary Howard Lutnick in the US capital on Thursday (local time). In the meeting, the two sides reaffirmed their commitment to striking a trade deal before the Aug. 1 deadline and agreed to soon hold an additional round of negotiations, according to the Seoul government. "The market appears to have been relieved on news that Korea's industry minister and trade minister met with Lutnick, but the KOSPI showed limited growth due to persisting uncertainties ahead of the looming negotiation deadline," Lee Kyoung-min, an analyst at Daishin Securities, said. In Seoul, tech giant Samsung Electronics edged down 0.15 percent to 65,900 won, while its chipmaking rival SK hynix lost 1.3 percent to 266,000 won. Leading battery maker LG Energy Solution shed 1.22 percent, reflecting Tesla's 8.2 percent slide overnight. Bio shares also lost ground, with Samsung Biologics falling more than 2 percent to 1.06 million won and Celltrion down 1.33 percent to 178,000 won. Top automaker Hyundai Motor went down 0.46 percent to 216,500 won and its sister Kia retreated 0.86 percent to 104,100 won as they both posted a decrease in operating profits in the second quarter mainly due to the effects of 25 percent tariffs on all imported cars imposed by the Donald Trump administration. On the other hand, financial and shipbuilding shares delivered strong performances. KB Financial climbed 1.37 percent to 118,800 won and Shinhan Financial advanced 2.74 percent to 71,200 won. Major shipbuilder HD Hyundai Heavy soared 5.83 percent to 444,500 won, and its rival Hanwha Ocean gained 1.35 percent to 90,000 won on expectations for cooperation in the sector with the US Internet portal operator Naver also jumped 3.3 percent to 234,500 won, while Kakao Pay, the fintech arm of Kakao, shot up 10.71 percent on massive purchases by global investment bank Goldman Sachs. The local currency was quoted at 1,377.9 won against the US dollar at 3:30 p.m., down 10.7 won from the previous session. (Yonhap)
Korea Herald
12 hours ago
- Korea Herald
Miracell launches Korea's first generative AI voice system for hospitals
Korean stem cell research company Miracell has introduced the nation's first generative AI-powered voice consultation system designed for medical institutions. Co-developed with Europe-based Vee, a Warsaw-listed AI company, the solution marks a major shift in healthcare automation. The company said Monday it has secured exclusive distribution rights for Vee's AI solution across Asia and is working closely with Vee Korea to customize the system for local hospitals. Unlike traditional rule-based ARS systems, the new AI tool uses natural language processing to deliver 24-hour conversational support, handling appointment scheduling, billing inquiries, patient reminders and general questions. The system is particularly effective during nights and weekends, when staffing is limited. It integrates with hospital customer relationship management systems and supports both inbound and outbound calls. Hospitals can trial the solution free for one month, lowering the adoption barrier. 'Generative AI can dramatically improve service quality in medical care,' said Shin Hyun-soon, CEO of Miracell. 'This isn't just an upgrade — it's a survival strategy for the health care sector.' Vee provides the underlying large language model engine, customized for Korean language and clinical context. A future version will link with Miracell's Celldoc platform, integrating patient consultations, appointments, and treatment records into a single interface. By combining its stem cell expertise with cutting-edge AI, Miracell aims to set a new standard in the health care industry. 'We're starting with clinics already using Smart-MCell,' a Miracell spokesperson said. 'But this is just the beginning. With AI, we hope to bring patients and caregivers even closer, and open the door to a more responsive, intelligent health care experience.'
